Q3 2025 Business Update and Financial Results November 13 2025 This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company's estimates based on such sources. This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the Europea ...

Core Insights - Apogee Therapeutics, Inc. is actively participating in several upcoming investor conferences, showcasing its commitment to engaging with the investment community [1][2][3] Conference Participation - Apogee will participate in the Guggenheim 2 Annual Healthcare Innovation Conference on November 11, 2025, at 1:30 p.m. ET [2] - The company will also be present at the Stifel 2025 Healthcare Conference on November 12, 2025, at 11:20 a.m. ET [2] - Additionally, Apogee will take part in the TD Cowen Immunology and Inflammation Virtual Summit on November 13, 2025, at 12:30 p.m. ET [2] - The Jefferies London Healthcare Conference is scheduled for November 19, 2025, at 3:00 p.m. GMT / 10:00 a.m. ET [2] - The Citi 2025 Global Healthcare Conference will occur on December 3, 2025, at 9:45 a.m. ET [3] - A live and archived webcast of these events will be available on the Apogee Therapeutics website [3] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for major inflammatory and immunology (I&I) markets [4] - The company targets conditions such as Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [4] - Apogee's lead program, APG777, is primarily aimed at treating AD, which is identified as a significant and under-penetrated market [4] - The company has four validated targets in its portfolio and aims to achieve best-in-class profiles through both monotherapies and combinations of its novel antibodies [4] - Apogee believes its broad pipeline and expertise can provide substantial value and benefits to patients who are underserved by current treatment options [4]

Core Insights - Genmab A/S is a biotech innovator focusing on antibody engineering and has a strategy that includes direct commercialization of its products Tivdak and Epcoritamab, as well as monetizing through partnerships and licensing drugs like Darzalex and Kesimpta [1] Group 1 - The company retains its value through innovative antibody engineering [1] - Genmab's strategy involves both direct product sales and partnerships for drug monetization [1]